ClinicalTrials.gg
CompletedNCT00824850PILOTUpdated Nov 11, 2011Results posted

Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

A Phase 2 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 8 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-11.

Sponsored by Pfizer · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
8 Years to 16 Years
Sex
All
01

Study summary

The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the Northern California Kaiser Permanente (NCKP) health plan.

02

Conditions studied

  • Pneumococcal Conjugate Vaccine

Keywords

  • Single site
  • single dose
  • Participated in Wyeth D118-P8
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully vaccinated per-protocol (4 doses of vaccine given at 2, 4, 6, and 12-15 months of age) subjects enrolled in the Prevnar arm of Study D118-P8, OR
  • Fully vaccinated per-protocol subjects from the control arm of the same study that did not receive Prevnar after the close of Study D118-P8, or at any time following the study, AND
  • Still enrolled in NCKP health plan.
  • Subjects included in either group above must be in good health as determined by medical history, physical examination, and clinical judgment.

Exclusion criteria

Exclusion Criteria:

  • Previous receipt of pneumococcal polysaccharide vaccine.
  • History of documented recurrent pneumococcal otitis media or any occurence of pneumonia within past 12 months
  • History of documented invasive pneumococcal disease (defined as a positive culture of S. pneumoniae from a normally sterile body site).
  • Known or suspected disease or dysfunction of the immune system, including:
  • infection
  • Receipt of therapy
  • Sickle cell hemoglobinopathy
  • Concomitant vaccination during the study period.
  • Known to any component of Prevnar.
  • Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of, the study, or could preclude the evaluation of the subject's response.
  • Receipt of immune globulin within the past 3 months.
  • Positive pregnancy test for menarchal female subjects.
  • Females who are breastfeeding.
  • For control subjects, previous receipt of Prevnar at any time.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    1

    Subjects received Prevnar in study D118-P8

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    2

    Subjects received MnCC in study D118-P8

    Biological: 13-valent Pneumococcal Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)

    Percentage of participants achieving predefined IgG antibody threshold ≥0.35 micrograms per milliliter (Mcg/mL) for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% confidence intervals (CIs) based on the observed percentage of participants.

    Time frame: Day 28 (Visit 5)

  2. Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)

    Percentage of participants achieving predefined IgG antibody threshold ≥0.35 Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants.

    Time frame: Day 7 (Visit 4)

  3. Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)

    Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

    Time frame: Day 28 (Visit 5)

  4. Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)

    Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

    Time frame: Day 7 (Visit 4)

  5. Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)

    Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.

    Time frame: Day 28 (Visit 5)

  6. Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)

    Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.

    Time frame: Day 7 (Visit 4)

Secondary outcomes

  1. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

    Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 28 (Visit 5)

  2. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

    Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 28 (Visit 5)

  3. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

    Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 7 (Visit 4)

  4. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

    Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 7 (Visit 4)

  5. Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 28 (Visit 5)

  6. Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 28 (Visit 5)

  7. Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 7 (Visit 4)

  8. Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Baseline (Visit 1), Day 7 (Visit 4)

  9. Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)

    Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Day 28 (Visit 5)

  10. Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)

    Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Day 7 (Visit 4)

  11. Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Day 28 (Visit 5)

  12. Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

    Time frame: Day 7 (Visit 4)

Other outcomes

  1. Percentage of Participants Reporting Pre-specified Local Reactions Within 4 Days After Vaccination

    Local reactions reported using the diary card during the 4-day reactogenicity period after vaccination. Tenderness at injection site scaled as Any (tenderness present) or Significant (present and interfered with limb movement). Redness and swelling at injection site scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); or Severe (\> 7.0 cm). Participants may be represented in \>1 category.

    Time frame: Baseline up to 4 days after vaccination on Day 1

  2. Percentage of Participants Reporting Pre-specified Systemic Events Within 4 Days After Vaccination

    Systemic events reported using the diary card during the 4-day reactogenicity period after vaccination. Temperature scaled as Fever ≥38 but ≤39 degrees Celsius (C) (mild), \>39 but ≤40 degrees C (moderate), or \>40 degrees C (severe). Presence of Decreased appetite, Irritability, Increased sleep, Decreased sleep, Rash, and Hives; also scaled as Mild (easily tolerated, minimal discomfort; not interfering with activities), Moderate (sufficiently discomforting to interfere with normal activities), or Severe (may prevent normal activities and require medical intervention).

    Time frame: Baseline up to 4 days after vaccination on Day 1

07

Results

Posted Nov 11, 2011

Participant flow

Participants were previously enrolled in Prevnar protocol D118-P8 (study duration 1995 to 1998) and were randomized to receive either 7-valent pneumococcal conjugate vaccine or meningococcal C conjugate vaccine in that study.

Participant flow — Overall Study
Milestone7vPnC / 13vPnCMnCC / 13vPnC
Started3837
Received vaccination 13vpnc3836
Completed3836
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)

Percentage of participants achieving predefined IgG antibody threshold ≥0.35 micrograms per milliliter (Mcg/mL) for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% confidence intervals (CIs) based on the observed percentage of participants.

Time frame:
Day 28 (Visit 5)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)
observed percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 4100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 6B100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 9V100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 14100.0 (90.7 to 100.0)97.1 (85.1 to 99.9)
7vPnC serotype 18C100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 19F100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 23F100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 1100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 394.7 (82.3 to 99.4)97.0 (84.2 to 99.9)
Additional serotype 5100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 6A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 7F100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 19A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 2.9 · 95% CI -6.9 to 14.9
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.2 · 95% CI -15.7 to 10.9
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
PrimaryPercentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)

Percentage of participants achieving predefined IgG antibody threshold ≥0.35 Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants.

Time frame:
Day 7 (Visit 4)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)
observed percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 494.7 (82.3 to 99.4)85.7 (69.7 to 95.2)
7vPnC serotype 6B100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 9V100.0 (90.7 to 100.0)97.1 (85.1 to 99.9)
7vPnC serotype 14100.0 (90.7 to 100.0)94.3 (80.8 to 99.3)
7vPnC serotype 18C97.4 (86.2 to 99.9)94.3 (80.8 to 99.3)
7vPnC serotype 19F100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 23F100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 1100.0 (90.7 to 100.0)97.1 (85.1 to 99.9)
Additional serotype 394.7 (82.3 to 99.4)87.9 (71.8 to 96.6)
Additional serotype 5100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 6A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 7F100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 19A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 9.0 · 95% CI -5.6 to 25.5
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 2.9 · 95% CI -6.9 to 14.9
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 5.7 · 95% CI -4.2 to 19.2
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 3.1 · 95% CI -9.3 to 17.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 2.9 · 95% CI -6.9 to 14.9
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 6.9 · 95% CI -7.4 to 23.4
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
PrimaryPercentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)

Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

Time frame:
Day 28 (Visit 5)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)
observed percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 4100.0 (90.3 to 100.0)100.0 (89.1 to 100.0)
7vPnC serotype 6B100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 9V100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 14100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 18C100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 19F97.4 (86.2 to 99.9)100.0 (89.7 to 100.0)
7vPnC serotype 23F100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 1100.0 (90.7 to 100.0)97.1 (84.7 to 99.9)
Additional serotype 3100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 589.5 (75.2 to 97.1)88.6 (73.3 to 96.8)
Additional serotype 6A100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
Additional serotype 7F100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 19A97.4 (86.2 to 99.9)100.0 (90.0 to 100.0)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.2 to 10.9
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.6 · 95% CI -13.9 to 8.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 2.9 · 95% CI -6.7 to 15.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.9 · 95% CI -15.0 to 17.6
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.6 · 95% CI -13.9 to 7.6
PrimaryPercentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)

Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

Time frame:
Day 7 (Visit 4)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)
observed percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 497.4 (86.2 to 99.9)100.0 (89.7 to 100.0)
7vPnC serotype 6B100.0 (90.7 to 100.0)100.0 (89.4 to 100.0)
7vPnC serotype 9V100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 14100.0 (90.5 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 18C100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 19F94.3 (80.8 to 99.3)97.1 (84.7 to 99.9)
7vPnC serotype 23F97.3 (85.8 to 99.9)94.3 (80.8 to 99.3)
Additional serotype 1100.0 (90.5 to 100.0)97.1 (85.1 to 99.9)
Additional serotype 397.4 (86.2 to 99.9)100.0 (89.7 to 100.0)
Additional serotype 589.5 (75.2 to 97.1)88.2 (72.5 to 96.7)
Additional serotype 6A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 7F100.0 (90.5 to 100.0)97.0 (84.2 to 99.9)
Additional serotype 19A97.4 (86.2 to 99.9)100.0 (90.0 to 100.0)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.6 · 95% CI -13.9 to 8.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.2 to 10.6
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.8 · 95% CI -16.8 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 3.0 · 95% CI -9.1 to 16.6
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 2.9 · 95% CI -7.1 to 15.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.6 · 95% CI -13.9 to 8.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 1.2 · 95% CI -14.8 to 18.2
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 3.0 · 95% CI -6.8 to 15.8
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.6 · 95% CI -13.9 to 7.6
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 28 (Visit 5)
Reported as:
Geometric mean · Mcg/mL
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
Mcg/mL7vPnC / 13vPnC Prevaccination Visit 17vPnC / 13vPnC Postvaccination Visit 5
7vPnC serotype 40.20 (0.12 to 0.33)5.96 (4.10 to 8.65)
7vPnC serotype 6B5.89 (4.61 to 7.51)66.72 (50.19 to 88.70)
7vPnC serotype 9V1.54 (1.19 to 2.00)8.62 (6.55 to 11.34)
7vPnC serotype 140.58 (0.39 to 0.86)41.45 (27.72 to 61.97)
7vPnC serotype 18C0.75 (0.48 to 1.18)5.93 (4.34 to 8.11)
7vPnC serotype 19F2.94 (2.08 to 4.15)13.41 (8.89 to 20.23)
7vPnC serotype 23F2.51 (1.92 to 3.27)17.20 (12.44 to 23.77)
Additional serotype 11.04 (0.71 to 1.54)11.59 (7.34 to 18.30)
Additional serotype 31.30 (0.83 to 2.04)2.19 (1.60 to 2.99)
Additional serotype 53.24 (2.45 to 4.27)6.80 (4.75 to 9.74)
Additional serotype 6A3.78 (2.85 to 5.03)29.11 (19.04 to 44.50)
Additional serotype 7F1.38 (0.93 to 2.05)9.92 (7.03 to 14.01)
Additional serotype 19A7.05 (5.52 to 8.99)21.29 (14.90 to 30.43)
Statistical analysis
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 29.47 · 95% CI 17.61 to 49.33Confidence intervals (CI) for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 11.34 · 95% CI 8.49 to 15.13CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 5.58 · 95% CI 4.06 to 7.67CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 71.09 · 95% CI 40.74 to 124.08CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 7.91 · 95% CI 4.92 to 12.73CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 4.56 · 95% CI 2.87 to 7.26CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 6.85 · 95% CI 4.51 to 10.42CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 11.10 · 95% CI 6.98 to 17.64CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 1.68 · 95% CI 1.37 to 2.07CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 2.10 · 95% CI 1.52 to 2.90CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 7.70 · 95% CI 4.77 to 12.42CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 7.20 · 95% CI 4.95 to 10.48CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 3.02 · 95% CI 2.23 to 4.10CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 28 (Visit 5)
Reported as:
Geometric mean · Mcg/mL
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
Mcg/mLMnCC / 13vPnC Prevaccination Visit 1MnCC / 13vPnC Postvaccination Visit 5
7vPnC serotype 40.15 (0.07 to 0.29)2.86 (2.00 to 4.07)
7vPnC serotype 6B3.97 (2.78 to 5.67)22.62 (14.56 to 35.16)
7vPnC serotype 9V1.69 (1.20 to 2.38)4.70 (3.49 to 6.33)
7vPnC serotype 140.79 (0.43 to 1.43)18.50 (10.10 to 33.90)
7vPnC serotype 18C0.72 (0.46 to 1.13)9.79 (6.43 to 14.90)
7vPnC serotype 19F2.01 (1.32 to 3.05)18.02 (11.56 to 28.08)
7vPnC serotype 23F2.31 (1.70 to 3.14)20.80 (13.07 to 33.08)
Additional serotype 10.70 (0.43 to 1.15)5.30 (3.40 to 8.26)
Additional serotype 31.16 (0.73 to 1.86)1.81 (1.25 to 2.62)
Additional serotype 53.83 (2.77 to 5.31)7.39 (4.98 to 10.96)
Additional serotype 6A3.82 (2.79 to 5.23)17.05 (10.82 to 26.87)
Additional serotype 7F1.12 (0.73 to 1.72)5.94 (4.08 to 8.65)
Additional serotype 19A6.18 (4.57 to 8.35)20.17 (15.28 to 26.63)
Statistical analysis
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 19.68 · 95% CI 9.99 to 38.77CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 5.70 · 95% CI 3.90 to 8.33CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 2.78 · 95% CI 2.16 to 3.57CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 23.46 · 95% CI 13.17 to 41.79CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 13.68 · 95% CI 8.94 to 20.92CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 8.98 · 95% CI 6.21 to 12.97CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 9.00 · 95% CI 5.91 to 13.72CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 7.58 · 95% CI 5.36 to 10.72CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 1.56 · 95% CI 1.30 to 1.86CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 1.93 · 95% CI 1.43 to 2.60CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 4.46 · 95% CI 3.09 to 6.45CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 5.32 · 95% CI 3.65 to 7.75CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 3.27 · 95% CI 2.49 to 4.28CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 7 (Visit 4)
Reported as:
Geometric mean · Mcg/mL
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
Mcg/mL7vPnC / 13vPnC Prevaccination Visit 17vPnC / 13vPnC Postvaccination Visit 4
7vPnC serotype 40.20 (0.12 to 0.33)3.21 (2.10 to 4.90)
7vPnC serotype 6B5.89 (4.61 to 7.51)29.46 (20.74 to 41.86)
7vPnC serotype 9V1.54 (1.19 to 2.00)5.96 (4.57 to 7.76)
7vPnC serotype 140.58 (0.39 to 0.86)10.25 (6.85 to 15.33)
7vPnC serotype 18C0.75 (0.48 to 1.18)3.17 (2.26 to 4.42)
7vPnC serotype 19F2.94 (2.08 to 4.15)7.46 (5.43 to 10.25)
7vPnC serotype 23F2.51 (1.92 to 3.27)10.56 (7.69 to 14.51)
Additional serotype 11.04 (0.71 to 1.54)4.42 (2.93 to 6.67)
Additional serotype 31.30 (0.83 to 2.04)2.12 (1.54 to 2.92)
Additional serotype 53.24 (2.45 to 4.27)5.40 (4.08 to 7.15)
Additional serotype 6A3.78 (2.85 to 5.03)13.60 (9.01 to 20.53)
Additional serotype 7F1.38 (0.93 to 2.05)4.70 (3.26 to 6.78)
Additional serotype 19A7.05 (5.52 to 8.99)13.40 (10.30 to 17.42)
Statistical analysis
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 15.86 · 95% CI 9.16 to 27.46CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 5.01 · 95% CI 3.50 to 7.16CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 3.86 · 95% CI 2.93 to 5.09CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 17.57 · 95% CI 11.11 to 27.79CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 4.22 · 95% CI 2.86 to 6.23CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 2.54 · 95% CI 1.78 to 3.62CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 4.21 · 95% CI 2.86 to 6.19CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 4.23 · 95% CI 2.79 to 6.42CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 1.63 · 95% CI 1.30 to 2.05CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 1.67 · 95% CI 1.30 to 2.14CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 3.60 · 95% CI 2.39 to 5.42CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 3.41 · 95% CI 2.42 to 4.82CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 1.90 · 95% CI 1.60 to 2.26CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 7 (Visit 4)
Reported as:
Geometric mean · Mcg/mL
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
Mcg/mLMnCC / 13vPnC Prevaccination Visit 1MnCC / 13vPnC Postvaccination Visit 4
7vPnC serotype 40.15 (0.07 to 0.29)1.21 (0.70 to 2.11)
7vPnC serotype 6B3.97 (2.78 to 5.67)9.42 (6.23 to 14.24)
7vPnC serotype 9V1.69 (1.20 to 2.38)3.41 (2.51 to 4.65)
7vPnC serotype 140.79 (0.43 to 1.43)5.22 (2.76 to 9.86)
7vPnC serotype 18C0.72 (0.46 to 1.13)3.53 (2.16 to 5.76)
7vPnC serotype 19F2.01 (1.32 to 3.05)5.47 (3.51 to 8.54)
7vPnC serotype 23F2.31 (1.70 to 3.14)6.51 (4.24 to 10.01)
Additional serotype 10.70 (0.43 to 1.15)2.65 (1.75 to 4.00)
Additional serotype 31.11 (0.67 to 1.82)1.46 (0.97 to 2.20)
Additional serotype 53.83 (2.77 to 5.31)5.00 (3.49 to 7.15)
Additional serotype 6A3.82 (2.79 to 5.23)7.79 (5.17 to 11.72)
Additional serotype 7F1.12 (0.73 to 1.72)3.21 (2.25 to 4.59)
Additional serotype 19A6.18 (4.57 to 8.35)12.03 (8.83 to 16.39)
Statistical analysis
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 8.36 · 95% CI 4.50 to 15.56CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 2.37 · 95% CI 1.78 to 3.16CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 2.02 · 95% CI 1.63 to 2.49CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 6.61 · 95% CI 4.31 to 10.15CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 4.92 · 95% CI 3.34 to 7.26CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 2.73 · 95% CI 2.08 to 3.57CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 2.82 · 95% CI 2.08 to 3.83CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 3.79 · 95% CI 2.80 to 5.13CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 1.32 · 95% CI 1.11 to 1.57CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 1.30 · 95% CI 1.05 to 1.61CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 2.04 · 95% CI 1.51 to 2.75CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 2.87 · 95% CI 2.19 to 3.77CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 1.95 · 95% CI 1.59 to 2.39CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 28 (Visit 5)
Reported as:
Geometric mean · Titer
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
Titer7vPnC / 13vPnC Prevaccination Visit 17vPnC / 13vPnC Postvaccination Visit 5
7vPnC serotype 422 (6.3 to 80.7)4535 (2836.5 to 7251.3)
7vPnC serotype 6B1024 (488.4 to 2148.4)11939 (8748.1 to 16293.9)
7vPnC serotype 9V43 (13.4 to 137.3)6709 (5097.5 to 8829.4)
7vPnC serotype 14159 (63.7 to 396.0)5946 (4361.1 to 8107.6)
7vPnC serotype 18C54 (19.5 to 149.5)5067 (3375.1 to 7607.2)
7vPnC serotype 19F33 (15.1 to 73.3)1623 (995.2 to 2647.9)
7vPnC serotype 23F87 (34.1 to 223.4)2799 (2048.5 to 3823.2)
Additional serotype 16 (4.3 to 7.4)440 (301.8 to 641.2)
Additional serotype 311 (6.9 to 16.6)111 (87.1 to 141.1)
Additional serotype 54 (3.6 to 5.6)277 (145.2 to 526.4)
Additional serotype 6A17 (7.1 to 39.7)9029 (6255.0 to 13034.0)
Additional serotype 7F60 (17.7 to 205.3)7036 (4886.0 to 10131.8)
Additional serotype 19A76 (36.7 to 157.5)1869 (1099.8 to 3177.3)
Statistical analysis
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 201.8 · 95% CI 55.11 to 739.05CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 11.7 · 95% CI 5.20 to 26.10CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 156.4 · 95% CI 48.72 to 501.86CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 37.4 · 95% CI 13.71 to 102.31CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 93.9 · 95% CI 30.99 to 284.31CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 48.7 · 95% CI 23.27 to 101.97CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 32.1 · 95% CI 11.99 to 85.81CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 78.1 · 95% CI 50.42 to 120.94CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 10.3 · 95% CI 6.80 to 15.72CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 61.7 · 95% CI 32.75 to 116.34CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 536.5 · 95% CI 212.04 to 1357.19CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 116.9 · 95% CI 33.28 to 410.33CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 24.6 · 95% CI 11.30 to 53.42CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 28 (Visit 5)
Reported as:
Geometric mean · Titer
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5
TiterMnCC / 13vPnC Prevaccination Visit 1MnCC / 13vPnC Postvaccination Visit 5
7vPnC serotype 428 (4.5 to 174.3)4704 (2958.0 to 7481.1)
7vPnC serotype 6B288 (74.8 to 1106.9)11607 (7762.6 to 17354.1)
7vPnC serotype 9V120 (37.9 to 382.8)7457 (5702.3 to 9751.9)
7vPnC serotype 14262 (98.1 to 700.5)7006 (4997.7 to 9822.1)
7vPnC serotype 18C25 (8.4 to 75.7)5736 (4141.4 to 7943.8)
7vPnC serotype 19F23 (10.5 to 50.6)2696 (1831.0 to 3968.5)
7vPnC serotype 23F11 (5.0 to 23.5)5197 (3599.2 to 7503.1)
Additional serotype 15 (4.0 to 6.6)341 (221.9 to 524.9)
Additional serotype 311 (7.0 to 18.2)98 (75.2 to 126.9)
Additional serotype 54 (3.7 to 5.0)336 (175.4 to 642.2)
Additional serotype 6A24 (8.9 to 64.2)10488 (7460.6 to 14744.7)
Additional serotype 7F76 (21.1 to 275.2)6098 (4392.9 to 8464.9)
Additional serotype 19A39 (19.9 to 78.1)2424 (1696.6 to 3462.4)
Statistical analysis
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 168.8 · 95% CI 20.22 to 1409.76CI for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 40.3 · 95% CI 10.97 to 148.44CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 61.9 · 95% CI 18.83 to 203.72CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 26.7 · 95% CI 9.67 to 73.84CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 226.9 · 95% CI 79.81 to 645.29CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 116.8 · 95% CI 54.54 to 250.13CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 481.0 · 95% CI 207.01 to 1117.69CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 66.5 · 95% CI 41.80 to 105.75CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 8.6 · 95% CI 5.36 to 13.94CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 78.2 · 95% CI 41.38 to 147.80CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 438.1 · 95% CI 169.52 to 1132.43CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 80.0 · 95% CI 23.28 to 274.82CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 5 · Geometric mean fold rise: 61.5 · 95% CI 28.73 to 131.76CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 7 (Visit 4)
Reported as:
Geometric mean · Titer
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
Titer7vPnC / 13vPnC Prevaccination Visit 17vPnC / 13vPnC Postvaccination Visit 4
7vPnC serotype 419 (6.0 to 62.8)5449 (3118.6 to 9519.8)
7vPnC serotype 6B1034 (505.1 to 2116.9)7885 (5792.0 to 10734.0)
7vPnC serotype 9V43 (13.4 to 137.3)6497 (4357.4 to 9687.5)
7vPnC serotype 14148 (58.2 to 375.7)3497 (2440.8 to 5009.1)
7vPnC serotype 18C58 (20.6 to 163.8)5922 (3784.0 to 9268.9)
7vPnC serotype 19F40 (17.4 to 91.6)1243 (620.6 to 2489.8)
7vPnC serotype 23F79 (31.4 to 201.3)1487 (884.7 to 2499.5)
Additional serotype 16 (4.3 to 7.6)367 (228.8 to 587.3)
Additional serotype 311 (6.9 to 16.6)119 (82.1 to 172.0)
Additional serotype 54 (3.6 to 5.6)185 (100.9 to 337.5)
Additional serotype 6A17 (7.1 to 39.7)8072 (5195.8 to 12538.8)
Additional serotype 7F60 (17.7 to 205.3)4601 (2998.3 to 7060.6)
Additional serotype 19A76 (36.7 to 157.5)1345 (767.4 to 2357.7)
Statistical analysis
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 281.7 · 95% CI 76.65 to 1035.49CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 7.6 · 95% CI 3.47 to 16.75CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 151.4 · 95% CI 42.01 to 545.84CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 23.7 · 95% CI 8.67 to 64.54CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 102.1 · 95% CI 32.00 to 325.40CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 31.1 · 95% CI 12.71 to 76.13CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 18.7 · 95% CI 6.82 to 51.39CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 64.4 · 95% CI 37.33 to 111.18CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 11.1 · 95% CI 6.64 to 18.52CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 41.2 · 95% CI 23.09 to 73.48CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 479.6 · 95% CI 171.63 to 1339.96CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 76.4 · 95% CI 21.63 to 270.02CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • 7vPnC / 13vPnC Prevaccination Visit 1 vs 7vPnC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 17.7 · 95% CI 7.61 to 41.08CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryPneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Baseline (Visit 1), Day 7 (Visit 4)
Reported as:
Geometric mean · Titer
Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4
TiterMnCC / 13vPnC Prevaccination Visit 1MnCC / 13vPnC Postvaccination Visit 4
7vPnC serotype 440 (6.3 to 254.0)6782 (3687.6 to 12471.3)
7vPnC serotype 6B405 (103.5 to 1584.7)7195 (4585.5 to 11289.8)
7vPnC serotype 9V116 (36.8 to 364.9)7855 (5532.9 to 11152.1)
7vPnC serotype 14280 (103.1 to 760.7)6209 (4253.9 to 9063.3)
7vPnC serotype 18C25 (8.4 to 75.7)5193 (3658.1 to 7372.3)
7vPnC serotype 19F20 (9.4 to 44.7)1855 (1055.8 to 3258.2)
7vPnC serotype 23F11 (5.0 to 23.5)991 (501.3 to 1959.3)
Additional serotype 15 (4.0 to 6.5)385 (249.4 to 595.6)
Additional serotype 312 (7.2 to 19.0)101 (72.2 to 141.7)
Additional serotype 54 (3.7 to 5.0)258 (132.3 to 503.4)
Additional serotype 6A23 (8.7 to 59.1)6107 (4149.7 to 8987.5)
Additional serotype 7F95 (24.7 to 363.8)3577 (1774.8 to 7208.2)
Additional serotype 19A39 (19.9 to 78.1)1763 (1220.1 to 2547.6)
Statistical analysis
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 170.2 · 95% CI 22.24 to 1301.79CI for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 17.8 · 95% CI 5.27 to 59.91CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 67.8 · 95% CI 18.45 to 249.02CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 22.2 · 95% CI 7.94 to 61.88CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 205.5 · 95% CI 70.04 to 602.78CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 90.5 · 95% CI 40.28 to 203.27CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 91.7 · 95% CI 36.25 to 232.13CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 75.6 · 95% CI 47.32 to 120.91CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 8.7 · 95% CI 5.21 to 14.40CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 60.0 · 95% CI 31.06 to 115.92CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 269.8 · 95% CI 105.09 to 692.60CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 37.7 · 95% CI 10.85 to 131.09CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
  • MnCC / 13vPnC Prevaccination Visit 1 vs MnCC / 13vPnC Postvaccination Visit 4 · Geometric mean fold rise: 44.8 · 95% CI 21.31 to 94.01CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.
SecondaryComparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)

Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Day 28 (Visit 5)
Reported as:
Geometric mean · Mcg/mL
Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)
Mcg/mL7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 45.73 (4.21 to 7.81)2.92 (2.22 to 3.83)
7vPnC serotype 6B66.72 (50.19 to 88.70)22.62 (14.56 to 35.16)
7vPnC serotype 9V8.72 (6.68 to 11.40)4.70 (3.49 to 6.33)
7vPnC serotype 1441.45 (27.72 to 61.97)18.50 (10.10 to 33.90)
7vPnC serotype 18C5.72 (4.18 to 7.82)9.04 (5.98 to 13.68)
7vPnC serotype 19F14.17 (9.54 to 21.07)15.80 (10.00 to 24.96)
7vPnC serotype 23F17.20 (12.44 to 23.77)20.80 (13.07 to 33.08)
Additional serotype 19.55 (6.46 to 14.13)5.63 (3.67 to 8.64)
Additional serotype 32.13 (1.58 to 2.87)1.71 (1.20 to 2.44)
Additional serotype 56.80 (4.75 to 9.74)7.52 (5.12 to 11.04)
Additional serotype 6A29.11 (19.04 to 44.50)16.08 (10.18 to 25.40)
Additional serotype 7F9.92 (7.03 to 14.01)5.75 (3.98 to 8.33)
Additional serotype 19A21.29 (14.90 to 30.43)20.17 (15.28 to 26.63)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.97 · 95% CI 1.31 to 2.95CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 2.95 · 95% CI 1.78 to 4.90CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.85 · 95% CI 1.25 to 2.75CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 2.24 · 95% CI 1.11 to 4.53CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 0.63 · 95% CI 0.38 to 1.05CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 0.90 · 95% CI 0.50 to 1.62CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 0.83 · 95% CI 0.48 to 1.43CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.70 · 95% CI 0.96 to 3.00CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.25 · 95% CI 0.79 to 1.96CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 0.90 · 95% CI 0.54 to 1.52CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.81 · 95% CI 0.98 to 3.34CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.72 · 95% CI 1.05 to 2.83CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.06 · 95% CI 0.67 to 1.66CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
SecondaryComparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)

Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Day 7 (Visit 4)
Reported as:
Geometric mean · Mcg/mL
Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)
Mcg/mL7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 43.00 (2.07 to 4.35)1.37 (0.90 to 2.10)
7vPnC serotype 6B29.46 (20.74 to 41.86)9.42 (6.23 to 14.24)
7vPnC serotype 9V5.75 (4.40 to 7.51)3.41 (2.51 to 4.65)
7vPnC serotype 1410.25 (6.85 to 15.33)5.22 (2.76 to 9.86)
7vPnC serotype 18C3.09 (2.22 to 4.29)3.45 (2.16 to 5.52)
7vPnC serotype 19F7.66 (5.66 to 10.36)4.85 (3.09 to 7.62)
7vPnC serotype 23F10.56 (7.69 to 14.51)6.51 (4.24 to 10.01)
Additional serotype 13.98 (2.82 to 5.62)2.83 (1.86 to 4.32)
Additional serotype 32.02 (1.48 to 2.76)1.40 (0.95 to 2.06)
Additional serotype 55.40 (4.08 to 7.15)5.12 (3.60 to 7.28)
Additional serotype 6A13.60 (9.01 to 20.53)7.25 (4.75 to 11.06)
Additional serotype 7F4.70 (3.26 to 6.78)3.17 (2.24 to 4.48)
Additional serotype 19A13.40 (10.30 to 17.42)12.03 (8.83 to 16.39)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 2.18 · 95% CI 1.26 to 3.79CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 3.13 · 95% CI 1.84 to 5.32CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.68 · 95% CI 1.13 to 2.51CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.96 · 95% CI 0.95 to 4.07CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 0.90 · 95% CI 0.51 to 1.56CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.58 · 95% CI 0.93 to 2.66CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.62 · 95% CI 0.97 to 2.73CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.41 · 95% CI 0.83 to 2.39CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.44 · 95% CI 0.89 to 2.34CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.06 · 95% CI 0.68 to 1.64CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.88 · 95% CI 1.05 to 3.35CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.48 · 95% CI 0.90 to 2.44CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean concentrations: 1.11 · 95% CI 0.75 to 1.66CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
SecondaryComparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Day 28 (Visit 5)
Reported as:
Geometric mean · Titer
Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)
Titer7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 44626 (3322.5 to 6441.2)6065 (4590.9 to 8012.5)
7vPnC serotype 6B11451 (8290.4 to 15817.9)10380 (7515.2 to 14336.9)
7vPnC serotype 9V6346 (5152.2 to 7817.5)7555 (5916.7 to 9646.8)
7vPnC serotype 145898 (4481.0 to 7762.1)7031 (5195.6 to 9515.5)
7vPnC serotype 18C5090 (3428.4 to 7557.7)6005 (4389.3 to 8214.6)
7vPnC serotype 19F1623 (995.2 to 2647.9)2696 (1831.0 to 3968.5)
7vPnC serotype 23F2752 (2074.6 to 3651.3)4841 (3574.5 to 6555.1)
Additional serotype 1449 (312.8 to 643.2)347 (228.3 to 527.4)
Additional serotype 3113 (89.2 to 143.5)99 (77.0 to 126.3)
Additional serotype 5296 (158.8 to 549.9)336 (175.4 to 642.2)
Additional serotype 6A9458 (6674.2 to 13404.0)10842 (7904.9 to 14870.9)
Additional serotype 7F6740 (4933.2 to 9207.7)6050 (4515.0 to 8106.7)
Additional serotype 19A2120 (1308.0 to 3435.3)2340 (1667.0 to 3285.4)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.8 · 95% CI 0.50 to 1.17CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.1 · 95% CI 0.70 to 1.73CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.8 · 95% CI 0.61 to 1.15CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.8 · 95% CI 0.56 to 1.25CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.8 · 95% CI 0.51 to 1.40CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.6 · 95% CI 0.32 to 1.12CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.6 · 95% CI 0.38 to 0.85CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.3 · 95% CI 0.75 to 2.22CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.1 · 95% CI 0.82 to 1.61CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.9 · 95% CI 0.36 to 2.13CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.9 · 95% CI 0.55 to 1.39CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.1 · 95% CI 0.73 to 1.70CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.9 · 95% CI 0.50 to 1.63CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
SecondaryComparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.

Time frame:
Day 7 (Visit 4)
Reported as:
Geometric mean · Titer
Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)
Titer7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 45567 (3202.5 to 9678.7)8339 (6154.1 to 11299.5)
7vPnC serotype 6B8082 (5743.5 to 11372.6)6450 (4477.8 to 9290.2)
7vPnC serotype 9V6865 (4826.7 to 9763.7)7806 (5491.4 to 11095.6)
7vPnC serotype 143596 (2613.0 to 4948.5)5994 (4246.9 to 8460.1)
7vPnC serotype 18C5833 (3770.5 to 9023.7)5266 (3779.3 to 7338.4)
7vPnC serotype 19F1243 (620.6 to 2489.8)1855 (1055.8 to 3258.2)
7vPnC serotype 23F1575 (987.7 to 2511.7)1141 (655.1 to 1986.8)
Additional serotype 1379 (241.8 to 594.9)393 (257.2 to 600.3)
Additional serotype 3117 (81.3 to 167.5)104 (75.4 to 143.4)
Additional serotype 5200 (111.2 to 358.6)258 (132.3 to 503.4)
Additional serotype 6A8534 (5631.9 to 12931.6)6199 (4357.6 to 8818.6)
Additional serotype 7F4750 (3291.8 to 6852.9)3760 (2106.7 to 6709.5)
Additional serotype 19A1504 (911.2 to 2484.1)1761 (1242.8 to 2496.0)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.7 · 95% CI 0.35 to 1.27CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.3 · 95% CI 0.77 to 2.05CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.9 · 95% CI 0.54 to 1.44CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.6 · 95% CI 0.38 to 0.95CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.1 · 95% CI 0.64 to 1.91CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.7 · 95% CI 0.28 to 1.62CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.4 · 95% CI 0.68 to 2.81CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.0 · 95% CI 0.53 to 1.77CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.1 · 95% CI 0.69 to 1.81CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.8 · 95% CI 0.32 to 1.85CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.4 · 95% CI 0.80 to 2.36CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 1.3 · 95% CI 0.65 to 2.44CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Ratio of geometric mean titers: 0.9 · 95% CI 0.46 to 1.57CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures \[(7vPnC/13vPnC) - (MnCC/13vPnC)\].
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 4 Days After Vaccination

Local reactions reported using the diary card during the 4-day reactogenicity period after vaccination. Tenderness at injection site scaled as Any (tenderness present) or Significant (present and interfered with limb movement). Redness and swelling at injection site scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); or Severe (\> 7.0 cm). Participants may be represented in \>1 category.

Time frame:
Baseline up to 4 days after vaccination on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 4 Days After Vaccination
percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
Tenderness: Any92.186.1
Tenderness: Significant10.519.4
Swelling: Any10.55.6
Swelling: Mild2.62.8
Swelling: Moderate10.52.8
Redness: Any5.35.6
Redness: Mild0.02.8
Redness: Moderate5.32.8
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 4 Days After Vaccination

Systemic events reported using the diary card during the 4-day reactogenicity period after vaccination. Temperature scaled as Fever ≥38 but ≤39 degrees Celsius (C) (mild), \>39 but ≤40 degrees C (moderate), or \>40 degrees C (severe). Presence of Decreased appetite, Irritability, Increased sleep, Decreased sleep, Rash, and Hives; also scaled as Mild (easily tolerated, minimal discomfort; not interfering with activities), Moderate (sufficiently discomforting to interfere with normal activities), or Severe (may prevent normal activities and require medical intervention).

Time frame:
Baseline up to 4 days after vaccination on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 4 Days After Vaccination
percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
Fever ≥38 but ≤39 degrees C2.90.0
Decreased appetite7.916.7
Decreased appetite: Mild7.911.1
Decreased appetite: Moderate2.68.3
Irritability18.413.9
Irritability: Mild13.211.1
Irritability: Moderate5.35.6
Increased sleep26.333.3
Increased sleep: Mild15.825.0
Increased sleep: Moderate13.213.9
Increased sleep: Severe2.60.0
Decreased sleep7.911.1
Decreased sleep: Mild5.38.3
Decreased sleep: Moderate2.62.8
Rash5.30.0
Rash: Mild5.30.0
PrimaryPercentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)

Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.

Time frame:
Day 28 (Visit 5)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)
observed percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 4100.0 (90.3 to 100.0)100.0 (89.1 to 100.0)
7vPnC serotype 6B100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 9V100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 14100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 18C100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 19F100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 23F100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 1100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
Additional serotype 3100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 597.4 (86.2 to 99.9)94.3 (80.8 to 99.3)
Additional serotype 6A100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
Additional serotype 7F100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 19A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.2 to 10.9
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 3.1 · 95% CI -9.3 to 17.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
PrimaryPercentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)

Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.

Time frame:
Day 7 (Visit 4)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)
observed percentage of participants7vPnC / 13vPnCMnCC / 13vPnC
7vPnC serotype 497.4 (86.2 to 99.9)100.0 (89.7 to 100.0)
7vPnC serotype 6B100.0 (90.7 to 100.0)100.0 (89.4 to 100.0)
7vPnC serotype 9V100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 14100.0 (90.5 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 18C100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
7vPnC serotype 19F100.0 (90.0 to 100.0)100.0 (89.7 to 100.0)
7vPnC serotype 23F97.3 (85.8 to 99.9)94.3 (80.8 to 99.3)
Additional serotype 1100.0 (90.5 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 3100.0 (90.7 to 100.0)100.0 (89.7 to 100.0)
Additional serotype 597.4 (86.2 to 99.9)94.1 (80.3 to 99.3)
Additional serotype 6A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Additional serotype 7F100.0 (90.5 to 100.0)100.0 (89.4 to 100.0)
Additional serotype 19A100.0 (90.7 to 100.0)100.0 (90.0 to 100.0)
Statistical analysis
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: -2.6 · 95% CI -13.9 to 8.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.2 to 10.6
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.1 to 10.5
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 3.0 · 95% CI -9.1 to 16.6
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -10.0 to 10.1
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.4 to 10.3
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 3.3 · 95% CI -8.6 to 17.2
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.7 to 10.6
  • 7vPnC / 13vPnC vs MnCC / 13vPnC · Difference in proportions: 0.0 · 95% CI -9.5 to 10.0

Adverse events

Collected over Baseline up to Day 4 after vaccination for local reactions and systemic events or up to Day 194 (Visit 6 / Days 166 to 194 Follow-up Telephone Visit to assess AEs). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
7vPnC / 13vPnC—0/38 (0%)38/38 (100%)
MnCC / 13vPnC—0/36 (0%)36/36 (100%)
Most frequent other events
Showing 10 of 79
Most frequent other events
Event7vPnC / 13vPnCMnCC / 13vPnC
Tenderness: AnySkin and subcutaneous tissue disorders35/3831/36
Increased sleepGeneral disorders10/3812/36
Increased sleep: MildGeneral disorders6/389/36
Tenderness: SignificantSkin and subcutaneous tissue disorders4/387/36
IrritabilityGeneral disorders7/385/36
Decreased appetiteGeneral disorders3/386/36
Increased sleep: ModerateGeneral disorders5/385/36
Irritability: MildGeneral disorders5/384/36
Injection site painGeneral disorders4/384/36
Decreased appetite: MildGeneral disorders3/384/36

Baseline characteristics

Age Continuous
Age Continuous(years)7vPnC / 13vPnCMnCC / 13vPnCTotal
Mean12.6 ± 1.113.1 ± 0.912.8 ± 1.0
Sex: Female, Male
Sex: Female, Male(Participants)7vPnC / 13vPnCMnCC / 13vPnCTotal
Female151631
Male232144
08

Study locations

2 sites
  • Pfizer Investigational Site
    Hayward, California 94545, United States
  • Pfizer Investigational Site
    San Jose, California 95119, United States
09

References and documents

Publications

  • Klein NP, Ensor K, Jouve S, Northington R, Moscariello M, McGovern PC. Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Sep;32(9):990-7. doi: 10.1097/INF.0b013e3182959f34. PubMed 24008739 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2009
First posted
Jan 19, 2009
Start
Jan 2010
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Nov 11, 2011
Last update
Nov 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00824850
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 19, 2009
Start date
Jan 2010
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Nov 11, 2011
Last update
Nov 11, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion